NPO Stock Analysis: Enpro Industries | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 7.040m USD | 12M Return: 38% | US29355X1072 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.3M
EPS Trend: 73.9%
Qual. Beats: 0
Rev. Trend: 80.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Enpro Inc. (NYSE: NPO) is a U.S.-based industrial technology company that designs, manufactures, and markets proprietary products and solutions used to safeguard critical operating environments across the food, pharmaceutical, chemical, petrochemical, energy, aerospace, and semiconductor sectors. The company operates through two reporting segments: Sealing Technologies, which produces hygienic seals, gaskets, mechanical seals, expansion joints, and related components sold under brands such as Garlock, Gylon, Blue-Gard, Bio-Pro, and LINK-SEAL; and Advanced Surface Technologies, which provides precision-machined wafer processing sub-systems, cleaning and refurbishment services for semiconductor manufacturing equipment, optical filters, thin-film coatings, and edge-welded metal bellows for semiconductor, space, aerospace, and defense applications.
The business follows a diversified, multi-segment industrial model in which a broad portfolio of niche, mission-critical components is sold primarily to business customers rather than end consumers, with revenue generated across the United States, Europe, and Asia Pacific. Enpro was incorporated in 2002 and is headquartered in Charlotte, North Carolina, having rebranded from EnPro Industries, Inc. in December 2023.
- Semiconductor wafer processing demand drives Advanced Surface Technologies growth
- Food and pharma hygienic sealing sales offset industrial cyclicality
- Data center and AI chip buildouts boost cleaning and coating services backlog
| Net Income: 44.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.06 > 1.0 |
| NWC/Revenue: 20.89% < 20% (prev 23.53%; Δ -2.64% < -1%) |
| CFO/TA 0.08 > 3% & CFO 218.9m > Net Income 44.1m |
| Net Debt (524.5m) to EBITDA (199.9m): 2.62 < 3 |
| Current Ratio: 2.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (21.1m) vs 12m ago -0.47% < -2% |
| Gross Margin: 42.78% > 18% (prev 42.81%; Δ -0.03% > 0.5%) |
| Asset Turnover: 48.60% > 50% (prev 45.49%; Δ 3.11% > 0%) |
| Interest Coverage Ratio: 2.74 > 6 (EBIT TTM 92.9m / Interest Expense TTM 33.9m) |
| A: 0.10 (Total Current Assets 455.2m - Total Current Liabilities 199.5m) / Total Assets 2.66b |
| B: 0.46 (Retained Earnings 1.23b / Total Assets 2.66b) |
| C: 0.04 (EBIT TTM 92.9m / Avg Total Assets 2.52b) |
| D: 1.48 (Book Value of Equity 1.59b / Total Liabilities 1.07b) |
| Altman-Z'' = 3.94 = AA |
| DSRI: 1.06 (Receivables 169.6m/140.9m, Revenue 1.22b/1.08b) |
| GMI: 1.00 (GM 42.81% / 42.78%) |
| AQI: 1.01 (AQ_t 0.74 / AQ_t-1 0.74) |
| SGI: 1.13 (Revenue 1.22b / 1.08b) |
| TATA: -0.07 (NI 44.1m - CFO 218.9m) / TA 2.66b) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at USD 307.68 with a total of 164,556 shares traded. Over the past week, the price has changed by -2.61%, over one month by +2.19%, over three months by -3.62% and over the past year by +37.97%.
Current recommended Stop Loss: 277.20 (which is 9.9% or 2.6 ATR below the current price).
Enpro Industries has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy NPO.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 389.5 | 26.6% |
P/E Trailing = 161.4369
P/E Forward = 28.0899
P/S = 5.7522
P/B = 4.0733
P/EG = 1.8751
Revenue TTM = 1.22b USD
EBIT TTM = 92.9m USD
EBITDA TTM = 199.9m USD
Long Term Debt = 575.3m USD (from longTermDebt, last quarter)
Short Term Debt = 13.2m USD (from shortTermDebt, last quarter)
Debt = 601.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.0m
Net Debt = 524.5m USD (calculated: Debt 601.5m - CCE 77.0m)
Enterprise Value = 7.56b USD (7.04b + Debt 601.5m - CCE 77.0m)
Interest Coverage Ratio = 2.74 (Ebit TTM 92.9m / Interest Expense TTM 33.9m)
EV/FCF = 46.29x (Enterprise Value 7.56b / FCF TTM 163.4m)
FCF Yield = 2.16% (FCF TTM 163.4m / Enterprise Value 7.56b)
FCF Margin = 13.35% (FCF TTM 163.4m / Revenue TTM 1.22b)
Net Margin = 3.60% (Net Income TTM 44.1m / Revenue TTM 1.22b)
Gross Margin = 42.78% ((Revenue TTM 1.22b - Cost of Revenue TTM 700.3m) / Revenue TTM)
Gross Margin QoQ = 43.98% (prev 42.90%)
Tobins Q-Ratio = 2.84 (Enterprise Value 7.56b / Total Assets 2.66b)
Interest Expense / Debt = 5.64% (Interest Expense 33.9m / Debt 601.5m)
Taxrate = 22.08% (12.5m / 56.6m)
NOPAT = 72.4m (EBIT 92.9m * (1 - 22.08%))
Current Ratio = 2.28 (Total Current Assets 455.2m / Total Current Liabilities 199.5m)
Debt / Equity = 0.38 (Debt 601.5m / totalStockholderEquity, last quarter 1.59b)
Debt / EBITDA = 2.62 (Net Debt 524.5m / EBITDA 199.9m)
Debt / FCF = 3.21 (Net Debt 524.5m / FCF TTM 163.4m)
Total Stockholder Equity = 1.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.75% (Net Income 44.1m / Total Assets 2.66b)
RoE = 2.84% (Net Income TTM 44.1m / Total Stockholder Equity 1.55b)
RoCE = 4.36% (EBIT 92.9m / Capital Employed (Equity 1.55b + L.T.Debt 575.3m))
RoIC = 3.00% (NOPAT 72.4m / Invested Capital 2.41b)
WACC = 11.27% (E(7.04b)/V(7.64b) * Re(11.86%) + D(601.5m)/V(7.64b) * Rd(5.64%) * (1-Tc(0.22)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.78 | Cagr: 0.0%
[DCF] Terminal Value 67.59% ; FCFF base≈157.0m ; Y1≈171.8m ; Y5≈216.4m
[DCF] Fair Price = 78.83 (EV 2.19b - Net Debt 524.5m = Equity 1.67b / Shares 21.2m; r=11.27% [WACC]; 5y FCF grow 10.93% → 2.50% )
EPS Correlation: 73.92 | EPS CAGR: 10.93% | SUE: 0.53 | # QB: 0
Revenue Correlation: 80.27 | Revenue CAGR: 4.97% | SUE: 2.51 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.42 | Chg30d=+3.73% | Revisions=+40% | Analysts=4
EPS current Year (2026-12-31): EPS=9.59 | Chg30d=+3.72% | Revisions=+40% | GrowthEPS=+21.2% | GrowthRev=+15.1%
EPS next Year (2027-12-31): EPS=10.89 | Chg30d=+5.04% | Revisions=+50% | GrowthEPS=+13.5% | GrowthRev=+7.8%
[Analyst] Revisions Ratio: +70% (up=7, down=0)